相关临床试验
265
33 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1952
进行中（未招募）
11
4.2%
已完成
108
40.8%
Enrolling By Invitation
4
1.5%
尚未招募
18
6.8%
招募中
77
29.1%
终止
10
3.8%
Unknown
4
1.5%
撤回
33
12.4%
暂无批准数据
- Four children with thalassemia have been successfully cured using CS-101, a novel DNA base editing therapy developed by CorrectSequence Therapeutics in China, marking a significant breakthrough in genetic treatment. - The therapy uses a transformer base editor (tBE) to precisely correct disease-causing DNA mutations, with patients showing complete recovery in as little as five weeks after a single injection. - Clinical trials led by Professor Zhai Xiaowen at Fudan University Children's Hospital have demonstrated promising results, with the treatment now advancing to larger-scale trials in China, the US, and UK.
- A retrospective study at Children's Hospital of Fudan University demonstrates that belimumab combined with standard therapy achieved 97.1% renal response rate in childhood lupus nephritis, compared to 80% with standard therapy alone. - Children receiving belimumab showed faster treatment response within 3 months and maintained better outcomes through 24 months, with significantly higher sustained response rates. - The belimumab group achieved superior steroid reduction, with 82.9% of patients reaching glucocorticoid doses below 7.5mg daily at 12 months, compared to 30.4% in the standard therapy group.
